GRI Bio, Inc.
corporate_fare Company Profile
GRI Bio, Inc. (NASDAQ:GRI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for GRI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for GRI spans 10-Q, DEF 14A, 8-K, 10-K.
Recent high-impact activity:
- GRI Bio Q3 Loss Narrows to $1.5M; Going Concern and Nasdaq MVLS Risk Persist
- GRI Bio Seeks 546,529-Share Equity Plan Expansion, Lifting Overhang to 21%
- GRI Bio Unveils Phase 2a Biomarker Data Showing Repair Phenotype in IPF
- GRI Bio to Unveil Phase 2a IPF Data at ERS 2026: Lung Function, Biomarkers, Tolerability
- GRI Bio's Q2 Loss, Going Concern Doubt, and Nasdaq Delisting Risk
Financial Snapshot
Short Interest & Short Volume
1.56 days to coverFINRA reported short interest of 66,510 shares in GRI as of the October 30, 2026 settlement, a 0.6% increase from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 32.4% of GRI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.